AskGene Pharma

AskGene Pharma focuses development on unmet therapeutic needs and has a product pipeline in oncology, autoimmune disease, and ophthalmology.

AskGene Pharma's SmartKine platform is a cytokine prodrug platform intended to unlock the therapeutic potential of cytokine molecules.

The author bio is not yet written; admin@ask-gene.com has contributed 17 entries.

AskGene Pharma announced first-patient dosing in China for its Phase III trial of ASKB589, a CLDN18.2-targeting antibody tested with CAPOX and a PD-1 inhibitor for advanced gastric and gastroesophageal junction cancers.

The author bio is not yet written; raincastle has contributed 2 entries.

AffaMed Therapeutics (“AffaMed”), in collaboration with Askgene, announces that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712) for the treatment of retinal vascular diseases.

AskGene says two gastric cancer patients had partial responses after six weeks of ASKB589 monotherapy in its ongoing Phase I/II trial.

(Camarillo, California and Nanjing, Jiangsu Province, China) Askgene announces the acceptance of IND to initiate a clinical trial of ASKG712 to treat nAMD (neovascular age related macular degeneration) from NMPA (National Medical Products Administration) in China.

AskGene Pharma announced that partner AffaMed dosed the first patient in a US Phase 1 study of ASKG712 (AM712), which blocks VEGF and Ang-2 and is being studied for retinal diseases.

AskGene Pharma offers work in the cytokine therapy field.

AskGene Pharma develops cytokine prodrugs.

AskGene Pharma says it works with complementary partners to bring cytokine therapies into medical practice.

Find contact information for AskGene Pharma Inc., a global leader in the development of novel cytokine prodrugs and originator of the SmartKine platform.

AskGene Pharma develops cytokine prodrugs for oncology and autoimmune disease and has a SmartKine platform.

Askgene Pharma says visitors can browse its website without sharing personal information; information submitted through contact may be shared with partners, consultants, and service providers to respond to inquiries.